SCHEMBL1508161

SCHEMBL1508161

[O-][S+](CC1CCCCC1)C(c1ccc(F)cc1)(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 3/20 0.34
ALDH1A1 P00352 1/20 0.33
TRPA1 O75762 1/20 0.33
KLK7 P49862 2/20 0.32
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
LMNA P02545 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
CTSL P07711 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507912 0.75 NPC1 (0.37) RAB9ANPC1TRPA1PSEN1PSEN2
SCHEMBL1508154 0.71 NPC1 (0.44) RAB9APOLBSMN1; SMN2NPC1ALDH1A1
SCHEMBL14543805 0.70 RAB9A (0.41) RAB9APOLBSMN1; SMN2NPC1ALDH1A1
SCHEMBL14066322 0.68 KCNN4 (0.40) POLBSMN1; SMN2ALDH1A1LMNA
SCHEMBL1508205 0.66 KCNN4 (0.38) RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4
SCHEMBL23396257 0.65 MAOB (0.55) RAB9APOLBSMN1; SMN2ALDH1A1TRPA1
SCHEMBL1508101 0.65 RAB9A (0.39) RAB9APOLBSMN1; SMN2NPC1TRPA1
SCHEMBL1507904 0.65 KMT2A (0.37) RAB9APOLBSMN1; SMN2NPC1ALDH1A1
SCHEMBL14394798 0.64 POLB (0.51) RAB9APOLBSMN1; SMN2ALDH1A1TRPA1
SCHEMBL2370080 0.64 POLB (0.51) RAB9APOLBSMN1; SMN2ALDH1A1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 RAB9A 1508/4885POLB 4811/4885SMN1; SMN2 3752/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 RAB9A 1508/4885POLB 4811/4885SMN1; SMN2 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.